September 13, 2021. Ophthotech agreed to pay $29 million to end a securities class action lawsuit that was brought against the company in the Southern District of New York. Plaintiff alleged that Ophthotech misrepresented the scope and outcomes of clinical studies regarding the macular degeneration drug Fovista. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert analysis on market efficiency and the computation of damages.


Additional information is available at Bloomberg Law and Law360.